Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients

被引:0
|
作者
Zhang, Xiaomin [1 ]
Yang, Jieli [1 ]
Chen, Sai [1 ]
Liu, Chang [1 ]
Wang, Zhenhua [1 ]
Ren, Hefei [1 ]
Zhou, Lin [1 ]
机构
[1] Naval Med Univ, Shanghai Changzheng Hosp, Dept Lab Med, 415 Fengyang Rd, Shanghai 200003, Peoples R China
基金
中国国家自然科学基金; 芬兰科学院;
关键词
Hypertension; Multiple myeloma; Progression-free survival; Risk stratification; BLOOD-PRESSURE; PARATHYROID-HORMONE; CANCER; RISK; CELLS; INTERLEUKIN-6; INFLAMMATION; MEDICATIONS; CALCIUM;
D O I
10.1007/s11239-022-02653-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately 31% of patients diagnosed with multiple myeloma (MM) have pre-existing hypertension, but its effects on patient survival have not been investigated. We collected data from 228 newly diagnosed patients with MM and found that 71 (31.1%) had pre-existing hypertension. The impact of pre-existing hypertension on MM patients was determined by evaluating progression-free survival (PFS). Kaplan-Meier analyses revealed a significantly lower PFS in the pre-existing hypertension group than their non-hypertensive counterparts (median 22.6 vs 34.8 months, respectively). The multivariable Cox proportional hazards model showed that pre-existing hypertension was an independent risk factor for PFS reduction in MM patients. Moreover, the risk of disease progression in MM patients with pre-existing hypertension was higher than in non-hypertension comparator patients (hazard ratio 1.735, 95% confidence interval 1.261-2.387). In MM patients with pre-existing hypertension, Kaplan-Meier analyses found that those with a higher risk of hypertension had a significantly shorter PFS than those with lower risk (median 19.3 vs 25.4 months, respectively). However, multivariate Cox regression analysis showed that the risk stratification of hypertension was not an independent risk factor for poor PFS in MM patients with pre-existing hypertension. Our study demonstrates that pre-existing hypertension was significantly associated with a lower PFS in newly diagnosed MM patients.
引用
收藏
页码:542 / 549
页数:8
相关论文
共 50 条
  • [21] Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej J.
    Kumar, Shaji
    Medhekar, Rohan
    Pei, Huiling
    Lefebvre, Patrick
    Kaila, Shuchita
    He, Jianming
    Lafeuille, Marie-Helene
    Cortoos, Annelore
    Londhe, Anil
    Mavros, Panagiotis
    Lin, Thomas S.
    Usmani, Saad Z.
    ONCOLOGIST, 2022, 27 (07): : E589 - E596
  • [22] Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
    Jennifer L. J. Heaney
    John P. Campbell
    Gulnaz Iqbal
    David Cairns
    Alex Richter
    J. Anthony Child
    Walter Gregory
    Graham Jackson
    Martin Kaiser
    Roger Owen
    Faith Davies
    Gareth Morgan
    Janet Dunn
    Mark T. Drayson
    Leukemia, 2018, 32 : 1727 - 1738
  • [23] Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
    Heaney, Jennifer L. J.
    Campbell, John P.
    Iqbal, Gulnaz
    Cairns, David
    Richter, Alex
    Child, J. Anthony
    Gregory, Walter
    Jackson, Graham
    Kaiser, Martin
    Owen, Roger
    Davies, Faith
    Morgan, Gareth
    Dunn, Janet
    Drayson, Mark T.
    LEUKEMIA, 2018, 32 (08) : 1727 - 1738
  • [24] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Sonneveld, Pieter
    Manier, Salomon
    Lam, Annette
    Roccia, Tito
    Schecter, Jordan M.
    Cost, Patricia
    Pacaud, Lida
    Poirier, Abbey
    Tremblay, Gabriel
    Lan, Tommy
    Valluri, Satish
    Kumar, Shaji
    BMC CANCER, 2024, 24 (01)
  • [25] Soluble MICA as a prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
    Rebmann, V.
    Schuett, P.
    Brandhorst, D.
    Opalka, B.
    Nowrousian, M. R.
    Moritz, T.
    Grosse-Wilde, H.
    TISSUE ANTIGENS, 2007, 69 (05): : 390 - 390
  • [26] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [27] Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
    Rosenberg, Aaron S.
    Facon, Thierry
    Parikh, Kejal
    Chung, Weiyuan
    Srinivasan, Shankar
    Kotey, Stanley
    Tuscano, Joseph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05): : 345 - +
  • [28] Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma
    Cohen, Jonathon B.
    Ruppert, Amy S.
    Heerema, Nyla A.
    Andritsos, Leslie A.
    Jones, Jeffrey A.
    Porcu, Pierluigi
    Baiocchi, Robert
    Christian, Beth A.
    Byrd, John C.
    Flynn, Joseph
    Penza, Sam
    Devine, Steven M.
    Blum, Kristie A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (05): : 278 - 285
  • [29] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    M Hussein
    A S Swern
    D Weber
    Leukemia, 2011, 25 : 1620 - 1626
  • [30] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Hussein, M.
    Swern, A. S.
    Weber, D.
    LEUKEMIA, 2011, 25 (10) : 1620 - 1626